NEW YORK, NY, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Innovative Warehouse Solutions (IWS), a leading New York-based eCommerce fulfillment company, has officially signed a partnership deal with Amazon Shipping, Amazon's small parcel delivery network. Historically focused solely on supporting Amazon's own eCommerce operations, Amazon Shipping now reaches 90% of the U.S. population with transit speeds that compete with UPS Ground and USPS Ground Advantage. In 2024 alone, the service delivered 5.7 billion packages, ...

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly making materially false and misleading statements regarding its business and the effectiveness of its product, nimacimab, during the specified Class Period from November 4, 2024, to October 3, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Skye Bioscience's defendants misrepresented the effectiveness of nimacimab, overstating its clinical, regulatory, and commercial prospects [5]. - Investors who purchased Skye securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the court by January 16, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Perrigo Company plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - PRGONovember 21, 2025 8:41 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 21, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Perrigo Company plc (NYSE: PRGO) between February 27, 2023 and November 4, 2025, both dates inclus ...

Nov 21, 2025 8:38 PM Eastern Standard Time PRGO Investors Have Opportunity to Lead Perrigo Company plc Securities Fraud Lawsuit with the Schall Law Firm Share LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Perrigo Company plc ("Perrigo†or "the Company†) (NYSE: PRGO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and ...

Question-and-Answer SessionMarcio SouzaPresident, CEO & Director Absolutely, and it's always a pleasure to be here. Like there is always a lot. I feel every time we talk that there's a lot going on with the company, and we're very pleased and happy with that, but it still remain quite humble on the heels of a very successful essential tremor readout on both studies. So we have that filing coming up, hopefully early in the year, by early in the year. A number of epilepsy assets progressing, including our DEE ...

Investors should pay attention to this under-the-radar favorite among smart money stocks. Celestica (CLS 0.79%) has become an increasingly favored investment by smart money, with $6.32 billion in institutional inflows and $4.28 billion in institutional outflows over the last 12 months. Large funds, including Viking Global Investors, Divisadero Street, Balyasny , and Lazard, have dramatically increased their stakes in the stock in the third quarter of 2025. Here's why smart money seems to like this stock. Gr ...

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

Nov 21, 2025 8:22 PM Eastern Standard Time Enviri Corporation Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Enviri Corporation - NVRI Share NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF†) are investigating the proposed sale of Enviri Corporation's (NYSE: NVRI) Clean Earth to Veolia Environnement SA. U ...

Core Viewpoint - AstraZeneca has committed to investing $50 billion in U.S. production and R&D by 2030, with a recent announcement of a $2 billion investment in Maryland to expand biologics manufacturing facilities [2][7][20]. Investment and Expansion - The $2 billion investment includes expanding an existing biologics manufacturing facility and constructing a new clinical manufacturing unit in Maryland [2][5]. - This investment is part of a broader $50 billion commitment to enhance U.S. manufacturing and R&D capabilities over the next five years [7][20]. Job Creation - The construction of the new facilities is expected to create approximately 2,600 jobs, including positions for highly skilled scientists, technicians, engineers, and construction workers [6][5]. Financial Performance - AstraZeneca's share price has increased by 15% over the past year, reflecting positive market sentiment and strong performance in oncology [7][19]. - The company aims to achieve $80 billion in revenue by 2030, with half of that revenue expected to come from the U.S. market [19][20]. Clinical Development and Innovation - AstraZeneca has a strong portfolio in breast cancer treatments, with promising data presented at recent oncology conferences [9][10]. - The company is actively investing in various disease areas, including hypertension, with recent successful phase three results for a new drug [21][22]. Strategic Positioning - AstraZeneca is transitioning to a listing on the New York Stock Exchange to enhance visibility and accessibility for U.S. investors [19][21]. - The company is focused on balancing the need to reduce drug prices while maintaining its leadership in biopharmaceutical innovation [16][18].

Core Viewpoint - Metalero Mining Corp. is extending its price protection for a non-brokered private placement to December 9, 2025, to complete subscriptions for its Offering [1] Group 1: Offering Details - The Offering consists of up to 1,428,572 flow-through units priced at $0.21 per unit, each unit includes one flow-through common share and one common share purchase warrant [2] - Each warrant allows the holder to purchase an additional non flow-through common share at a price of $0.26 for two years from issuance [2] - The first tranche of the Offering closed on October 21, 2025, with the sale of 952,381 flow-through units [2] Group 2: Use of Proceeds - Proceeds from the Offering will be utilized to support the Fall 2025 exploration work at the Benson Project, including further sampling and ground geophysics [3] Group 3: Tax Implications - All flow-through shares offered qualify as "flow-through shares" under the Income Tax Act (Canada), and qualifying individuals under the BC Tax Act will have these expenditures qualify as "BC flow-through mining expenditures" [4] Group 4: Conditions and Approvals - The Offering is subject to conditions including necessary approvals from the TSX Venture Exchange, and all securities issued will have a hold period of four months and a day after the closing date [5] Group 5: Company Overview - Metalero Mining Corp. is a Canadian junior exploration company focused on copper and gold projects in North America, with its flagship Benson Project covering 166 square kilometers and hosting five prospects containing gold and copper [7]